Halozyme Therapeutics vs Universal Health Services

Halozyme Therapeutics (HALO), health care, and Universal Health Services (UHS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Halozyme Therapeutics and Universal Health Services are valued at about the same: $10.9B and $11.1B. Halozyme Therapeutics trades at 24.0 times earnings and Universal Health Services at 8.0; operating margins in their latest fiscal years were 33.6% and 11.5%. Over the past year Halozyme Therapeutics's share price has moved +37.7% and Universal Health Services's -13.6%.

Key facts

Halozyme Therapeutics market value
$10.9B
Universal Health Services market value
$11.1B
Halozyme Therapeutics P/E
24.0
Universal Health Services P/E
8.0
Halozyme Therapeutics revenue
$1.4BFY to 2025-12-31
Universal Health Services revenue
$17.4BFY to 2025-12-31
Superinvestors holding both
2

Market values as of .

Halozyme Therapeutics vs Universal Health Services: every measure side by side
Measure Halozyme Therapeutics Universal Health Services
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.9Blower$11.1Bhigher
Revenue$1.4Blower$17.4Bhigher
Earnings$316.9Mlower$1.5Bhigher
Employees423lower102,000higher
Total assets$2.5Blower$15.5Bhigher
Valuation
P/E24.0higher8.0lower
P/S7.8higher0.6lower
P/B—1.5
Dividend yield0.00%lower0.40%higher
Profitability
Operating margin33.6%higher11.5%lower
Balance sheet
Net assets$48.8Mlower$7.3Bhigher
Total liabilities$2.5Blower$8.1Bhigher
Total debt$2.1Blower$4.8Bhigher
Cash on hand$133.8Mlower$137.8Mhigher
Price change
Today-0.55%higher-2.94%lower
1 year+37.7%higher-13.6%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (2)

Universal Health Services only (3)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Halozyme Therapeutics / Universal Health Services). Who owns HALO · Who owns UHS

Further comparisons

Learn

Questions and answers

Which is bigger, Halozyme Therapeutics or Universal Health Services?

By market value, Universal Health Services is the larger: $11.1B against $10.9B for Halozyme Therapeutics. By revenue in its latest fiscal year, Universal Health Services is the larger: $17.4B against $1.4B for Halozyme Therapeutics.

Which has the higher P/E ratio?

Halozyme Therapeutics: 24.0, against 8.0 for Universal Health Services. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Halozyme Therapeutics: 33.6%, against 11.5% for Universal Health Services. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Universal Health Services: 0.40%, against 0.00% for Halozyme Therapeutics. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Universal Health Services: $4.8B, against $2.1B for Halozyme Therapeutics. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Halozyme Therapeutics and Universal Health Services?

In their latest 13F filings, Josef Lakonishok and Ray Dalio (founder) hold both.

Cite this page

Funkfolio, “Halozyme Therapeutics vs Universal Health Services”, data as of 18 November 2026. https://funkfolio.com/compare/halo-vs-uhs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.